Literature DB >> 22924168

Phenazepam and cannabinomimetics sold as herbal highs in New Zealand.

R A F Couch1, H Madhavaram.   

Abstract

A smokeable product called Kronic, is legally available, sold under five product names, and marketed in New Zealand as containing natural extracts. Two such products called Pineapple Express and Purple Haze were purchased from shops in Auckland city. They were investigated for the presence of synthetic drugs specifically synthesized for recreational purposes. The synthetic cannabinomimetics identified were JWH-018, JWH-073, JWH-122, JWH-250, and 1-pentyl-3-(4-methoxybenzoyl)indol. A compound not previously reported in such designer drug preparations 1-butyl-3-(4-methoxybenzoyl)indol was also seen. There was a marked variation in the content of these compounds within a named brand. The pharmaceutical benzodiazepine phenazepam (fenazepam) was identified as a constituent, along with certain cannabinominetics, in nearly all of the Kronic samples examined. Phenazepam has not previously been reported as a constituent of designer drug or herbal high products. The amount of phenazepam was approximately 1 mg per gram of Kronic leaf material. Use of these products could result in severe toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22924168     DOI: 10.1002/dta.349

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  3 in total

Review 1.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

Review 2.  'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.

Authors:  Laura Orsolini; John M Corkery; Stefania Chiappini; Amira Guirguis; Alessandro Vento; Domenico De Berardis; Duccio Papanti; Fabrizio Schifano
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 3.  Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Authors:  Pietro Brunetti; Raffaele Giorgetti; Adriano Tagliabracci; Marilyn A Huestis; Francesco Paolo Busardò
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.